Sharps Technology

Sharps Technology

Sharps Technology, incorporated in Nevada and headquartered in New York, was founded in 2017. Chief Executive Officer Robert Hayes guided the company onto the public markets through an initial public offering in 2022, listing on the Nasdaq under the ticker STSS. The firm operates as a medical device company, and its entry into public markets coincided with the construction of a manufacturing facility in South Carolina intended to support domestic production of its proprietary syringe technologies. Sharps Technology centers its product line on a dual-chamber safety syringe designed to reduce needle-stick injuries and minimize vaccine waste. The company has entered into distribution agreements to place its syringes into global health channels, including a notable supply agreement with a Latin American distribution partner focused on vaccine delivery in 2022. Its asset-light model licenses manufactured products through partners while it builds out its own assembly capacity, targeting a dual revenue stream from direct sales of Sharps-branded devices and contract manufacturing for third-party pharmaceutical firms in North America and Latin America. The company has not publicly disclosed total assets under management, as it operates as an operating business rather than an investment firm. Its physical footprint expanded in 2023 with the progression of its injection-molding facility near Columbia, South Carolina, a project partially supported by county-level economic development incentives. In November 2023, the company completed an asset purchase agreement to acquire a syringe manufacturing facility from a specialty pharmacy provider, expanding its production capacity. The company's scale remains small, with its market capitalization fluctuating in the micro-cap range, and it had approximately a dozen full-time employees as of its last public filings. A structural differentiator for Sharps Technology is its function as a publicly traded pure-play manufacturer of a specific safety device, rather than a diversified medical-technology conglomerate. Investors gain exposure to a single product thesis: the global regulatory shift away from traditional disposable syringes toward auto-disabling and ultra-low-dead-space designs. This concentrated mandate creates binary execution risk around manufacturing scale-up and procurement contract wins, setting it apart from larger, multi-line competitors.